| SKU:K1324 | M. Wt:468.47 | ||
| Formula:C25H23F3N4O2 | Solubility:No | ||
| Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
| CAS No.:366017-09-6 | Synonyms:TAK 165, TAK165 | ||
| Chemical NameN/A | |||
| 供货周期： | 7天 |
| 品牌： | |
| 型号： | 10mg |
| 货号： | K1324 |
| CAS号： | 366017-09-6 |
| SKU:K1324 | M. Wt:468.47 | ||
| Formula:C25H23F3N4O2 | Solubility:No | ||
| Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
| CAS No.:366017-09-6 | Synonyms:TAK 165, TAK165 | ||
| Chemical NameN/A | |||
| Description | Mubritinib(TAK 165) | |||||
|---|---|---|---|---|---|---|
| Targets | ErbB2 | |||||
| IC50 | 6 nM | |||||
| In vitro | TAK-165 can inhibit HT1376, UMUC3, T24 (bladder), ACHN (kidney), DU145, LNCaP, LN-REC4 (prostate) cell lines, which are observed HER2 expression, with IC50 from 0.09 to greater than 25 micromol/L. The prostate cancer cell lines are all sensitive to mubritinib (TAK 165).Mubritinib (TAK 165) can inhibit prostate cancer cell lines with IC50 from 0.053to 4.62 micromol/L. | |||||
| In vivo | In the xenograft model, treatment with TAK-165 significantly inhibited growth of UMUC-3, ACHN, and LN-REC4. The antitumor effect (T/C [%]=growth of TAK-165 treated tumor/average growth of control tumorx100) after 14 days treatment were 22.9%, 26.0%, and 26.5% in UMUC3, ACHN and LN-REC4, respectively. | |||||
| Clinical Trials | N/A | |||||
| Features | N/A | |||||
重组人肌球蛋白轻链2(Recombinant Human MYL2)
重组大鼠抵抗素(Rat Resistin)
大鼠酸性磷酸酶(ACP)ELISA Kit
大鼠胆囊收缩素/缩胆囊素八肽(CCK-8)ELISA Kit
人瘦素(LEP)ELISA Kit
重组人半乳糖凝集素16/LGALS16 Human
重组人半乳糖凝集素8/Human LGALS8 His
重组人半乳糖凝集素3/Human LGALS3 His
重组人卵泡抑素/Human FST His
重组人β防御素118/DEFB118 Human
重组人心肌营养素1/CTF1 Human
特级新生牛血清（无支原体）
超级新生牛血清（无支原体）
优级胎牛血清（无支原体）
特级新生牛血清（无噬菌体低内毒素）
工商信息
信息已认证
联系方式
详细地址
关注
拨打电话
留言咨询
